These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15793367)

  • 1. Pharmacokinetic profiling and bioequivalence evaluation of 2 lamivudine tablet formulations after single oral administration in healthy human Indian volunteers.
    Narang VS; Lulla A; Malhotra G; Purandare S
    J Acquir Immune Defic Syndr; 2005 Apr; 38(5):566-9. PubMed ID: 15793367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects.
    Narang VS; Lulla A; Malhotra G; Purandare S
    J Clin Pharmacol; 2005 Mar; 45(3):265-74. PubMed ID: 15703362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profiling and bioequivalence assessment of two marketed brands of nevirapine tablets in healthy Indian volunteers.
    Narang VS; Lulla A; Malhotra G; Purandare S
    Arzneimittelforschung; 2005; 55(10):598-603. PubMed ID: 16294506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption.
    Moore KH; Shaw S; Laurent AL; Lloyd P; Duncan B; Morris DM; O'Mara MJ; Pakes GE
    J Clin Pharmacol; 1999 Jun; 39(6):593-605. PubMed ID: 10354963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
    Yuen GJ; Lou Y; Thompson NF; Otto VR; Allsup TL; Mahony WB; Hutman HW
    J Clin Pharmacol; 2001 Mar; 41(3):277-88. PubMed ID: 11269568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Rao Thudi N; Koundinya Tippabhotla S; Khuroo A; Marwah A; Kumar Shrivastav V; Tandon M; Raghuvanshi R; Biswal S
    Clin Ther; 2007 Dec; 29(12):2677-84. PubMed ID: 18201583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine/lamivudine/stavudine as a combined-formulation tablet: bioequivalence study compared with each component administered concurrently under fasting condition.
    Monif T; Tippabhotla SK; Garg M; Singla AK; Vijan T
    Int J Clin Pharmacol Ther; 2006 Jun; 44(6):276-83. PubMed ID: 16800100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence of two lamivudine tablet formulations.
    Santos-Magalhães NS; Pontes A; Cavalcante RM; Costa RM; Rangel FA; Guimarães MI; de Carvalho JN; de Souza SD; de Oliveira HM; Esteves IL; Ramalho MS; Vieira SL; Alves AJ
    Arzneimittelforschung; 2001; 51(4):310-4. PubMed ID: 11367872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence evaluation of a fixed dose combination lamivudine + stavudine tablet with concurrent administration of lamivudine tablet and stavudine capsule in healthy volunteers.
    Chachad S; Lulla A; Malhotra G; Purandare S
    Arzneimittelforschung; 2009; 59(10):537-40. PubMed ID: 19998583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence evaluation of two marketed brands of stavudine 40 mg capsules in healthy human South African volunteers.
    Narang VS; Lulla A; Malhotra G; Purandare S
    Pharmacol Res; 2004 Nov; 50(5):511-6. PubMed ID: 15458772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.
    Vezina HE; Henry K; Ravindran GD; Kurpad AV; Raj TD; Fox K; Weller D; Brundage RC; Cavert W; Balfour HH
    J Acquir Immune Defic Syndr; 2006 Feb; 41(2):131-6. PubMed ID: 16394842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects.
    Damle BD; Kaul S; Behr D; Knupp C
    J Clin Pharmacol; 2002 Jul; 42(7):791-7. PubMed ID: 12092746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
    Bittner B; Riek M; Holmes B; Grange S
    Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Reyar S; Tiwari HK; Tippabhotla SK; Khuroo A; Thudi NR; Ahmed S; Raghuvanshi R
    Arzneimittelforschung; 2009; 59(2):104-8. PubMed ID: 19338141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.
    Else LJ; Jackson A; Puls R; Hill A; Fahey P; Lin E; Amara A; Siccardi M; Watson V; Tjia J; Emery S; Khoo S; Back DJ; Boffito M
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1427-33. PubMed ID: 22183172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of lamivudine in human plasma by HPLC and its use in bioequivalence studies.
    Kano EK; dos Reis Serra CH; Koono EE; Andrade SS; Porta V
    Int J Pharm; 2005 Jun; 297(1-2):73-9. PubMed ID: 15907596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eslicarbazepine acetate (BIA 2-093) : relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations.
    Fontes-Ribeiro C; Nunes T; Falcão A; Neta C; Lima R; Tavares S; Almeida L; Macedo T; Soares-da-Silva P
    Drugs R D; 2005; 6(5):253-60. PubMed ID: 16128595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food.
    Weller S; Chen S; Borland J; Savina P; Wynne B; Piscitelli SC
    J Acquir Immune Defic Syndr; 2014 Aug; 66(4):393-8. PubMed ID: 24798770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized pahse I bioequivalence clinincal trial of a paediatric fixed-dose combination antiretroviral reconstitutable suspension in healthy adult volunteers.
    Esseku F; Joshi A; Oyegbile Y; Edowhorhu G; Gbadero D; Adeyeye M
    Antivir Ther; 2013; 18(2):205-12. PubMed ID: 23653910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.